[Platelet inhibition in acute coronary syndromes: a complex intervention that needs optimization].

نویسنده

  • Carlos Aguiar
چکیده

Na última década, a mortalidade por causas cardiovasculares tem diminuído em Portugal, mas a mortalidade por doença vascular cerebral declinou muito mais do que a mortalidade por doença cardíaca isquémica. Dados da Comissão Europeia mostram que do período 1998-2000 para o período 2007-2009, a mortalidade por doença vascular cerebral desceu de 145,2 para 78,5 mortes por 100 000 habitantes, enquanto a mortalidade por doença cardíaca isquémica apenas desceu de 65,7 para 44,6 mortes por 100 000 habitantes (taxas padronizadas para a idade). Segundo a Coordenação Nacional para as Doenças Cardiovasculares, dos 18 075 doentes admitidos no ano 2010 em Unidades de Cuidados Intensivos Cardíacos, 5320 foram admitidos por enfarte agudo do miocárdio (EAM) sem elevação do segmento ST e 4308 por EAM com elevação do segmento ST, correspondendo a um crescimento de 7,8 e 8,6%, respetivamente, face ao ano de 2009. A intervenção coronária percutânea (ICP) primária foi o método de reperfusão em 2838 doentes, mais 10,9% que no ano anterior. No ano 2009, houve 12 318 procedimentos de ICP -mais 6,6% do que no ano anterior -nos quais se implantaram 15 122 stents, sendo 10 590 farmacoativos. As síndromes coronárias agudas (SCA) requerem tratamento intensivo na fase aguda, para aliviar a isquemia miocárdica e prevenir a ocorrência de eventos adversos como a morte, o (re) EAM e as arritmias potencialmente fatais. Depois da «estabilização clínica» e da alta hospitalar, estes doentes mantêm taxas relativamente elevadas de complicações trombóticas, justificando prolongar a inten-

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Novel Strategies in Anti-Platelet Treatment for Coronary Artery Disease

Treatment with oral anti-platelet agents constitutes a cornerstone in the therapy of coronary artery disease. Coronary angioplasty and stent implantation improved the therapy of coronary artery disease and especially the treatment of acute myocardial infarction. Implementation of glycoprotein IIb/IIIa inhibition further advanced anti-platelet therapy as a central component in the treatment of a...

متن کامل

Post-cardioversion atrial fibrillation: the synthesis of modern concepts?

L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354: 1757–62. [8] The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary s...

متن کامل

Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes

Background—The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established. Methods and Results—We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban...

متن کامل

Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.

An indisputable body of angiographic, angioscopic, pathological, and biochemical evidence supports the role of thrombus in the pathogenesis of acute myocardial infarction, unstable angina, and percutaneous coronary intervention. Compelling data from large-scale trials and analyses have established the role of platelet inhibitors in reducing coronary events in patients with the acute coronary sy...

متن کامل

Vascular Medicine Suppression of Arterial Thrombosis Without Affecting Hemostatic Parameters With a Cell-Penetrating PAR1 Pepducin

Background—Thrombin-dependent platelet activation is heightened in the setting of percutaneous coronary intervention and may cause arterial thrombosis with consequent myocardial necrosis. Given the high incidence of adverse effects in patients with acute coronary syndromes, there remains an unmet need for the development of new therapeutics that target platelet activation without unduly affecti...

متن کامل

Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.

BACKGROUND Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndrome patients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup anal...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

دوره 31 4  شماره 

صفحات  -

تاریخ انتشار 2012